5.JPG)
Global Rare Kidney Diseases Market Size is valued at USD 2.9 Billion in 2024 and is predicted to reach USD 8.1 Billion by the year 2034 at a 11.0% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
Kidney diseases have the potential to intensify over time, eventually leading to kidney failure, which is when the kidneys completely stop working. In addition, having one of these diseases can put you at a higher risk for developing another condition, such as cardiovascular disease. At least 150 distinct conditions are classified as rare kidney diseases, and the majority are inherited. The diagnosis and treatment of rare kidney diseases as a group may present overlapping difficulties, even though individual cases of these diseases present unique obstacles. Diagnosis, management, and treatment of inherited kidney disorders are complicated, especially when multisystem complications are present. These diseases can result in numerous physical and mental impairments, lowering life expectancy and reducing the quality of life. In the last two years, the COVID-19 infection severely affected the human lifestyle and approach towards chronic disease treatment. This led to delayed detection of rare kidney diseases and became responsible for the increase in the number of patients.
Several important factors are responsible for the growth of the rare kidney disease market. It is anticipated that the increasing use of next-generation sequencing techniques will improve diagnostic accuracy for rare kidney diseases, aid in elucidating the molecular mechanism of disease, facilitate genetic counselling, and provide opportunities for carrier testing. Renal replacement therapy advancements and increased accessibility allow for more prolonged patient survival, but frequently at the expense of their quality of life. FDA approvals, Government initiatives and funding also contribute to expanding the market for such complicated diseases. In 2021, IgA nephropathy was rare kidney disease, and the FDA approved the first medication to reduce urine protein. The FDA had approved Tarpeyo (budesonide) delayed-release capsules to treat adults with primary immunoglobulin A (IgA) nephropathy who are at risk of rapid disease progression by lowering proteinuria (increased protein levels in the urine).
Multiple factors, including unresolved genetic defects, a lack of biomarkers to track disease progression, heterogeneous clinical phenotypes, and outdated diagnostic classifications that do not reflect underlying pathophysiological mechanisms, have impacted therapeutic advancements in rare kidney diseases. Slow drug approvals and complex studies will also restrain the market's growth.
The Rare Kidney Diseases market is segmented into target indications, type of molecule, and route of administration. Target indication segment includes IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy and others. Another segment is a type of molecule, which comprises Small Molecules and biologics. The subsegment biologics include Monoclonal Antibody, Hormone, Recombinant Protein, and Others. The last segment is the route of administration which has Oral, Intravenous, Subcutaneous, and other routes as subsegments.
According to regional analysis, North America will lead the global Rare Kidney Diseases market during the forecast period due to rapid clinical advancement breakthroughs and research for treatments of kidney diseases.
|
Report Attribute |
Specifications |
|
Market size value in 2024 |
USD 2.9 Billion |
|
Revenue forecast in 2034 |
USD 8.1 Billion |
|
Growth rate CAGR |
CAGR of 11.0 % from 2025 to 2034 |
|
Quantitative units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
Target Indication, Type of Molecule, Route of administration |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
GlaxoSmithKline, Recordati Rare Diseases, Amicus Therapeutics, Calliditas Therapeutics, Alexion Pharmaceuticals (A subsidiary of AstraZeneca), Travere Therapeutics, Aurinia Pharmaceutical, Advicenne, Protalix Biotherapeutics, AstraZeneca, Chinook Therapeutics, Reata Pharmaceuticals, Roche, Novartis Pharmaceuticals, Merk & co., Apellis Pharmaceuticals, Omeros Corporation, Lonza, and Other Prominent Players. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Rare Kidney Diseases Market Snapshot
Chapter 4. Global Rare Kidney Diseases Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Clinical Trial/Pipeline Analysis
4.8. Competitive Landscape & Market Share Analysis
4.9. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Target Indication Estimates & Trend Analysis
5.1. by Target Indication & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Target Indication:
5.2.1. IgA Nephropathy
5.2.2. Lupus Nephritis
5.2.3. Focal Segmental Glomerular Sclerosis
5.2.4. Membranous Nephropathy
5.2.5. C3 Glomerulopathy
5.2.6. Cystinosis
5.2.7. Dense Deposit Disease
5.2.8. Distal Renal Tubular Acidosis
5.2.9. Fabry Disease
5.2.10. Refractory Gout
5.2.11. Atypical Hemolytic Uremic Syndrome
5.2.12. Others
Chapter 6. Market Segmentation 2: by Type of Molecule Estimates & Trend Analysis
6.1. by Type Of Molecule & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Molecule:
6.2.1. Small Molecules
6.2.2. Biologics
6.2.2.1. Monoclonal Antibody
6.2.2.2. Hormone
6.2.2.3. Recombinant Protein
6.2.2.4. Others
Chapter 7. Market Segmentation 3: by Route of Administration Estimates & Trend Analysis
7.1. by Route Of Administration & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Route Of Administration:
7.2.1. Oral
7.2.2. Intravenous
7.2.3. Subcutaneous
7.2.4. Others
Chapter 8. Rare Kidney Diseases Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Rare Kidney Diseases Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
8.1.2. North America Rare Kidney Diseases Market Revenue (US$ Million) Estimates and Forecasts by Type Of Molecule, 2021-2034
8.1.3. North America Rare Kidney Diseases Market revenue (US$ Million) by Route Of Administration, 2021-2034
8.1.4. North America Rare Kidney Diseases Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Rare Kidney Diseases Market revenue (US$ Million) by Target Indication, 2021-2034
8.2.2. Europe Rare Kidney Diseases Market revenue (US$ Million) by Type of Molecule, 2021-2034
8.2.3. Europe Rare Kidney Diseases Market revenue (US$ Million) by Route of Administration, 2021-2034
8.2.4. Europe Rare Kidney Diseases Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Rare Kidney Diseases Market revenue (US$ Million) by Target Indication, 2021-2034
8.3.2. Asia Pacific Rare Kidney Diseases Market revenue (US$ Million) by Type of Molecule, 2021-2034
8.3.3. Asia-Pacific Rare Kidney Diseases Market revenue (US$ Million) by Route Of Administration, 2021-2034
8.3.4. Asia Pacific Rare Kidney Diseases Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Rare Kidney Diseases Market revenue (US$ Million) by Target Indication, 2021-2034
8.4.2. Latin America Rare Kidney Diseases Market revenue (US$ Million) by Type of Molecule, 2021-2034
8.4.3. Latin America Rare Kidney Diseases Market revenue (US$ Million) by Route of Administration, 2021-2034
8.4.4. Latin America Rare Kidney Diseases Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Rare Kidney Diseases Market revenue (US$ Million) by Target Indication, 2021-2034
8.5.2. Middle East & Africa Rare Kidney Diseases Market revenue (US$ Million) by Type of Molecule, 2021-2034
8.5.3. Middle East & Africa Rare Kidney Diseases Market revenue (US$ Million) by Route of Administration, 2021-2034
8.5.4. Middle East & Africa Rare Kidney Diseases Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. GlaxoSmithKline
9.2.2. Recordati Rare Diseases
9.2.3. Amicus Therapeutics
9.2.4. Calliditas Therapeutics
9.2.5. Alexion Pharmaceuticals (A subsidiary of AstraZeneca)
9.2.6. Travere Therapeutics
9.2.7. Aurinia Pharmaceutical
9.2.8. Advicenne
9.2.9. Protalix Biotherapeutics
9.2.10. AstraZeneca
9.2.11. Chinook Therapeutics
9.2.12. Reata Pharmaceuticals
9.2.13. Roche
9.2.14. Novartis Pharmaceuticals
9.2.15. Merk & co
9.2.16. Apellis Pharmaceuticals
9.2.17. Omeros Corporation
9.2.18. Other Prominent Players
Market Segmentation:
Global Rare Kidney Diseases Market, by Target Indication,
Lupus Nephritis
Focal Segmental Glomerular Sclerosis
Membranous Nephropathy
C3 Glomerulopathy
Cystinosis
Dense Deposit Disease
Distal Renal Tubular Acidosis
Fabry Disease
Refractory Gout
Atypical Hemolytic Uremic Syndrome
Others
Global Rare Kidney Diseases Market, by Type Of Molecule,
Global Rare Kidney Diseases Market, by Route Of Administration,
Global Rare Kidney Diseases Market, by Region,
North America Rare Kidney Diseases Market, by Country,
Europe Rare Kidney Diseases Market, by Country,
Asia Pacific Rare Kidney Diseases Market, by Country,
Latin America Rare Kidney Diseases Market, by Country,
Middle East & Africa Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
